시장보고서

상품코드

1498770

호흡기 감염증 치료 시장 : 감염 유형별, 약물 종류별, 투여 경로별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Respiratory Tract Infection Treatment Market, By Infection Type, By Drug Class, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 06월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 269 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

호흡기 감염증 치료 시장 규모는 2023년 432억 9,032만 달러로 2024년부터 2032년까지 연평균 6.10% 성장할 것으로 예상됩니다.

호흡기 감염증 치료 시장 - 시장 역학

소아 호흡기 감염증의 높은 유병률로 인해 호흡기 감염증 치료 시장의 수요가 증가

소아 호흡기 감염(RTI)의 높은 유병률로 인해 호흡기 감염증 치료 시장에서 효과적인 치료법의 필요성이 크게 증가하고 있습니다. 세계보건기구(WHO)에 따르면 급성호흡기감염증(ARI)은 5세 미만 어린이의 주요 사망 원인으로, 전 세계 이 연령대 사망의 약 20%를 차지합니다. 미국 질병예방통제센터(CDC)의 보고에 따르면, 매년 수백만 명의 어린이들이 폐렴, 기관지염 등 호흡기 감염으로 인해 의료적 개입이 필요한 경우가 많습니다. 이러한 부담의 증가는 고급 치료 옵션의 긴급한 필요성을 강조하고 의료 서비스 제공자와 부모가 이러한 감염과 싸우고 관련 건강 합병증을 줄이기위한 효과적인 솔루션을 찾고 있기 때문에 시장 수요를 주도하고 있습니다.

호흡기 감염증 치료 시장 - 주요 인사이트

당사의 리서치 애널리스트가 공유한 분석에 따르면, 세계 시장은 예측 기간(2024-2032) 동안 매년 약 6.10%의 CAGR로 성장할 것으로 예상됩니다.

감염 유형별로는 하기도 감염이 2023년 가장 큰 시장 점유율을 차지할 것으로 예상되었습니다.

약물 종류별로는 2023년 항생제가 주요 유형으로 나타났습니다.

투여 경로를 세분화하면 2023년에는 경구제가 주요 유형으로 나타났습니다.

지역별로는 북미가 2023년 매출에서 선두를 차지했습니다.

호흡기 감염증 치료 시장 - 세분화 분석:

세계 호흡기 감염증 치료 시장은 감염 유형, 약물 종류, 투여 경로, 최종사용자 및 지역을 기준으로 세분화됩니다.

시장은 감염 유형에 따라 '상기도 감염'과 '하기도 감염'의 두 가지 범주로 나뉩니다. 상기도 감염(UTI) 부문은 감기, 부비동염, 인후염 등 질환의 높은 발병률에 힘입어 시장을 주도할 것으로 예상됩니다. 반면, 하부 호흡기 감염(LRTI)은 특히 취약 계층에서 폐렴과 기관지염의 유병률 증가 등의 요인으로 인해 큰 폭의 성장이 예상됩니다.

약물 종류에 따라 시장은 항생제, 항바이러스제, 항진균제, 부신피질 스테로이드제, 기관지확장제 등 5가지 범주로 나뉩니다. 항생제는 박테리아에 의한 호흡기 감염증 치료에 널리 사용되기 때문에 시장 점유율을 주도할 것으로 예상됩니다. 항바이러스제는 특히 독감 등 바이러스성 호흡기 감염증 치료의 발전으로 인해 그 뒤를 이을 것으로 예상됩니다. 반면, 코르티코스테로이드, 항진균제, 기관지확장제는 특정 호흡기 질환과 환자의 필요에 따라 조정되기 때문에 점유율이 낮아질 것으로 예상됩니다.

호흡기 감염증 치료 시장 - 지리적 인사이트

호흡기 질환의 높은 유병률, 잘 정비된 의료 인프라, 연구 개발 활동의 중요성으로 인해 북미가 시장 점유율을 주도하고 있습니다. 유럽은 의료비 지출 증가, 유리한 상환 정책, 호흡기 질환에 취약한 노인 인구의 증가로 인해 그 뒤를 잇고 있습니다. 아시아태평양은 급속한 도시화, 오염 수준 증가, 호흡기 건강에 대한 인식 증가에 힘입어 큰 성장을 보일 것으로 예상됩니다. 이 지역의 인구 증가와 중산층 확대도 호흡기 감염증 치료에 대한 수요 증가에 기여하고 있습니다. 라틴아메리카와 중동 및 아프리카의 신흥 경제권 역시 의료 접근성 개선, 가처분 소득 증가, 의료 인프라 강화를 위한 정부의 노력에 힘입어 괄목할 만한 성장을 보이고 있습니다. 시장 기업들은 미개척 기회를 활용하고 탄탄한 발판을 마련하기 위해 전략적으로 이들 지역에 집중하고 있습니다.

호흡기 감염증 치료 시장 - 경쟁 상황:

시장의 주요 업체로는 글락소 스미스클라인, 노바티스, 화이자, 아스트라제네카, 사노피와 같은 제약회사가 있습니다. 이들 기업은 시장에서의 입지를 강화하기 위해 혁신적인 치료법 개발, 제품 포트폴리오 확장, 판매망 강화에 주력하고 있습니다. 또한, 시장 개척 기업들은 새로운 치료제를 도입하거나 기존 치료법을 개선하기 위한 연구개발에 많은 투자를 통해 의료진과 환자들의 변화하는 니즈에 대응하고 있습니다. 또한, 전문 지식, 자원, 규제 지원을 활용하기 위해 의료 기관, 학계, 정부 기관과 전략적 제휴를 맺는 사례도 늘고 있습니다. 효과적인 호흡기 감염증 치료에 대한 수요가 전 세계적으로 증가함에 따라 시장 경쟁은 더욱 치열해지고, 이 분야에서의 혁신과 발전은 더욱 가속화될 것으로 예상됩니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 : 호흡기 감염증 치료 업계

경쟁 대시보드
기업 개요
- AbbVie Inc.
- AstraZeneca plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Cipla Limited
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck &Co., Inc.
- Mylan NV(now part of Viatris Inc.)
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Others

제13장 애널리스트의 전방위 전망

ksm 24.06.27

REPORT HIGHLIGHT

Respiratory Tract Infection Treatment Market size was valued at USD 43,290.32 Million in 2023, expanding at a CAGR of 6.10% from 2024 to 2032.

The Respiratory Tract Infection Treatment Market, encompassing therapies and medications for ailments affecting the respiratory system, is poised for significant growth driven by the rising prevalence of respiratory diseases, increasing air pollution, and the growing geriatric population. Key driving factors include advancements in diagnostic technologies, increased healthcare expenditure, and heightened awareness of respiratory health. However, the market faces restraints such as stringent regulatory frameworks and potential side effects of treatments. Opportunities abound in the form of emerging markets, innovative drug development, and increasing adoption of telemedicine and personalized medicine, which are expected to enhance treatment efficacy and accessibility.

Respiratory Tract Infection Treatment Market- Market Dynamics

High Prevalence of Respiratory Tract Infections Among Children Fuels Need of the Respiratory Tract Infection Treatment Market

The high prevalence of respiratory tract infections (RTIs) among children is significantly fueling the need for effective treatments in the Respiratory Tract Infection Treatment Market. According to the World Health Organization (WHO), acute respiratory infections (ARIs) are a leading cause of death in children under five years old, accounting for approximately 20% of all deaths in this age group globally. The Centers for Disease Control and Prevention (CDC) report that millions of children are affected by respiratory infections such as pneumonia and bronchitis each year, often requiring medical intervention. This growing burden underscores the urgent need for advanced treatment options, driving demand in the market as healthcare providers and parents seek effective solutions to combat these infections and reduce associated health complications.

Respiratory Tract Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.10% over the forecast period (2024-2032)

Based on Infection Type segmentation, Lower Respiratory Tract Infections was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Antibiotics was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Respiratory Tract Infection Treatment Market- Segmentation Analysis:

The Global Respiratory Tract Infection Treatment Market is segmented on the basis of Infection Type, Drug Class, Route of Administration, End-User, and Region.

The market is divided into two categories based on Infection Type: Upper Respiratory Tract Infections, and Lower Respiratory Tract Infections. The upper Respiratory Tract Infections (URTI) segment is anticipated to dominate the market, driven by the high incidence of conditions such as common cold, sinusitis, and pharyngitis. Meanwhile, Lower Respiratory Tract Infections (LRTI) are expected to witness substantial growth due to factors including the rising prevalence of pneumonia and bronchitis, particularly among vulnerable populations.

The market is divided into five categories based on Drug Class: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids, and Bronchodilators. Antibiotics are expected to lead in market share, driven by their widespread use in treating respiratory infections caused by bacteria. Antiviral drugs are projected to follow, especially with advancements in treating viral respiratory infections like influenza. Meanwhile, corticosteroids, antifungal drugs, and bronchodilators are anticipated to have lower shares, tailored to specific respiratory conditions and patient needs.

Respiratory Tract Infection Treatment Market- Geographical Insights

North America leading in market share due to the high prevalence of respiratory diseases, well-established healthcare infrastructure, and strong emphasis on research and development activities. Europe follows suit, driven by increasing healthcare expenditure, favorable reimbursement policies, and a growing geriatric population prone to respiratory ailments. The Asia Pacific region is poised for significant growth, fueled by rapid urbanization, rising pollution levels, and increasing awareness of respiratory health. The region's large population base and expanding middle class also contribute to greater demand for respiratory tract infection treatments. Emerging economies in Latin America and the Middle East & Africa regions are also witnessing notable growth, propelled by improving healthcare access, rising disposable incomes, and government initiatives to enhance healthcare infrastructure. Market players strategically focus on these regions to capitalize on untapped opportunities and establish a strong foothold.

Respiratory Tract Infection Treatment Market- Competitive Landscape:

Major players in the market include pharmaceutical companies such as GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc, and Sanofi S.A. These companies focus on developing innovative treatments, expanding their product portfolios, and strengthening their distribution networks to enhance market presence. Market players also invest significantly in research and development to introduce novel therapeutics and improve existing treatment options, catering to the evolving needs of healthcare providers and patients. Moreover, strategic alliances with healthcare organizations, academic institutions, and government bodies are increasingly being forged to leverage expertise, resources, and regulatory support. With the growing demand for effective respiratory tract infection treatments worldwide, competition among market players is expected to intensify, leading to ongoing innovations and advancements in the field.

Recent Developments:

In July 2023, the FDA approved Beyfortus (nirsevimab-alip) jointly developed by Sanofi and AstraZeneca. It's a monoclonal antibody designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants and children under 24 months with a single intramuscular injection.

In May 2023, the FDA approved Arexvy, the inaugural RSV vaccine by GlaxoSmithKline Biologicals, for use in the United States. Arexvy is specifically indicated to prevent respiratory syncytial virus (RSV) and lower respiratory tract disease in individuals aged 60 and above.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.

AstraZeneca plc

Bayer AG

Boehringer Ingelheim International GmbH

Cipla Limited

F. Hoffmann-La Roche AG

Gilead Sciences, Inc.

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co., Inc.

Mylan N.V. (now part of Viatris Inc.)

Novartis AG

Pfizer Inc.

Sanofi S.A.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Others

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2019 - 2032

Upper Respiratory Tract Infections (URTI)
Lower Respiratory Tract Infections (LRTI)

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Antibiotics
Antiviral Drugs
Antifungal Drugs
Corticosteroids
Bronchodilators
Others

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable
Inhalation
Topical

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Clinics
Ambulatory Surgical Centers
Homecare Settings

GLOBAL RESPIRATORY TRACT INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Respiratory Tract Infection Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Respiratory Tract Infection Treatment Market Snippet by Infection Type
- 2.1.2. Respiratory Tract Infection Treatment Market Snippet by Drug Class
- 2.1.3. Respiratory Tract Infection Treatment Market Snippet by Route of Administration
- 2.1.4. Respiratory Tract Infection Treatment Market Snippet by End-User
- 2.1.5. Respiratory Tract Infection Treatment Market Snippet by Country
- 2.1.6. Respiratory Tract Infection Treatment Market Snippet by Region
2.2. Competitive Insights

3. Respiratory Tract Infection Treatment Key Market Trends

3.1. Respiratory Tract Infection Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Respiratory Tract Infection Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Respiratory Tract Infection Treatment Market Opportunities
3.4. Respiratory Tract Infection Treatment Market Future Trends

4. Respiratory Tract Infection Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Respiratory Tract Infection Treatment Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Respiratory Tract Infection Treatment Market Landscape

6.1. Respiratory Tract Infection Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Respiratory Tract Infection Treatment Market - By Infection Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Infection Type, 2023 & 2032 (%)
- 7.1.2. Upper Respiratory Tract Infections (URTI)
- 7.1.3. Lower Respiratory Tract Infections (LRTI)

8. Respiratory Tract Infection Treatment Market - By Drug Class

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 8.1.2. Antibiotics
- 8.1.3. Antiviral Drugs
- 8.1.4. Antifungal Drugs
- 8.1.5. Corticosteroids
- 8.1.6. Bronchodilators
- 8.1.7. Others

9. Respiratory Tract Infection Treatment Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Injectable
- 9.1.4. Inhalation
- 9.1.5. Topical

10. Respiratory Tract Infection Treatment Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Clinics
- 10.1.4. Ambulatory Surgical Centers
- 10.1.5. Homecare Settings

11. Respiratory Tract Infection Treatment Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Respiratory Tract Infection Treatment Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Respiratory Tract Infection Treatment Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Respiratory Tract Infection Treatment Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Respiratory Tract Infection Treatment Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Respiratory Tract Infection Treatment Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Respiratory Tract Infection Treatment Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. AbbVie Inc.
- 12.2.2. AstraZeneca plc
- 12.2.3. Bayer AG
- 12.2.4. Boehringer Ingelheim International GmbH
- 12.2.5. Cipla Limited
- 12.2.6. F. Hoffmann-La Roche AG
- 12.2.7. Gilead Sciences, Inc.
- 12.2.8. GlaxoSmithKline plc
- 12.2.9. Johnson & Johnson
- 12.2.10. Merck & Co., Inc.
- 12.2.11. Mylan N.V. (now part of Viatris Inc.)
- 12.2.12. Novartis AG
- 12.2.13. Pfizer Inc.
- 12.2.14. Sanofi S.A.
- 12.2.15. Sun Pharmaceutical Industries Ltd.
- 12.2.16. Teva Pharmaceutical Industries Ltd.
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us